AliveCor released its Kardia Pro artificial intelligence platform for atrial fibrillation to the U.S. market on Thursday. The company also announced it received $30 million in funding from Omron Healthcare and Mayo Clinic.

Heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. About 610,000 Americans die of the disease every year.

AliveCor's CEO Vic Gundotra stated that cardiologists want to see more than just ECGs from their patients to manage heart disease and stroke risk. They need the additional data to detect atrial fibrillation at an early stage.
The Kardia Pro platform tracks weight, activity and blood pressure and the artificial intelligence technology generates a personalized heart profile for each patient.

"Reviewing data this quickly lets me make important medical decisions, accelerating the time to diagnosis and avoiding unnecessary health care utilization," Dr. Theodore Takata, cardiac electrophysiologist in Forth Worth, Texas, said in a statement.

He added that Kardia can also empower his patients by making them more proactive in their own health care.

Omron Healthcare expanded its strategic partnership with AliveCor to redefine the role of technology in heart health. This is part of Omron's Going for Zero mission, launched in December, to eliminate heart attacks and strokes.

The funding from Omron, Mayo Clinic, and existing inside investors will help Kardia Pro become the new standard for preventing and detecting heart disease and stroke.

AliveCor will use any additional funds on developing more innovative heart health technologies and to expand its business.

Business Affairs Homepage